Amrein P C, Poulin R F, Coleman M, Richards F, Weil M, Kennedy B J, Carey R W, Green M R, Holland J F, Weinberg V
Am J Clin Oncol. 1984 Jun;7(3):269-71. doi: 10.1097/00000421-198406000-00014.
The activity of m-AMSA was evaluated IN 39 patients with advanced malignant melanoma. Seventy-nine percent of the patients had some prior chemotherapy. The others had some combination of surgery, radiotherapy, and immunotherapy prior to this study. Patients were treated every 3 weeks starting with 60 or 120 mg/m2 of m-AMSA depending on the extent of prior treatment. Doses were escalated if nadir WBC counts were greater than 2500/microliter. Leukopenia was the dose-limiting toxicity with 7.5% of patients having nadir WBC counts less than 1000/microliter. Of the 39 patients evaluable for response, all had progressive disease. In this study, m-AMSA in myelosuppressive doses was not active in malignant melanoma.
对39例晚期恶性黑色素瘤患者评估了m-AMSA的活性。79%的患者此前接受过某种化疗。其他患者在本研究之前接受过手术、放疗和免疫治疗的某种联合治疗。根据既往治疗程度，患者每3周接受一次治疗，起始剂量为60或120mg/m²的m-AMSA。如果最低点白细胞计数大于2500/微升，则增加剂量。白细胞减少是剂量限制性毒性，7.5%的患者最低点白细胞计数低于1000/微升。在可评估反应的39例患者中，所有患者病情均进展。在本研究中，骨髓抑制剂量的m-AMSA对恶性黑色素瘤无活性。
